Phase III
Polyphor announced that it has decided to close the Phase III PRISM MDR and UDR studies of murapavadin intravenous for hospital-acquired and ventilator-associated bacterial pneumonia which have been put on a voluntary temporary hold on May 9th, 2019.
With the latest major Phase 3 failure of Biogen and Eisai’s beta-amyloid-targeting antibody drug aducanumab, researchers are increasingly turning to other drug targets for Alzheimer’s disease.
Acacia Pharma Group plc welcomes an editorial published in the leading peer-reviewed journal Anesthesia & Analgesia, accompanying the print publication of results from its positive Phase 3 clinical trial of BARHEMSYS® as treatment of post-operative nausea & vomiting in patients who had not received prior prophylaxis*.
According to reports, Novartis veteran Jonathan Symonds is likely to be named the next chairman of the board.
The beginning of virtual clinical trials is going to be a game-changer. Why they are going to be game-changer? What changes will occur? Know it all here.
It was a typically busy week for clinical trials, with announcements in a wide variety of indications. Here’s a look.
The companies indicate they hope to continue data analysis to better understand the disease and will present anything relevant at a future scientific meeting.
The co-primary endpoints were pain freedom and freedom from the symptom that bothers the patient the most at two hours after receiving the drug. The trial hit its co-primary endpoints.
Companies from across Europe, Asia and around the globe share pipeline and business updates.
The two-drug combination of Dovato provided similar long-term viral suppression to common three-drug regimens.
PRESS RELEASES